SCHEMBL9270809

SCHEMBL9270809

Cc1cc(C=CC(=O)O)c(C)[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
EIF2AK2 P19525 1/20 0.42
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
NFKB1 P19838 2/20 0.40
CA4 P22748 2/20 0.40
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MIF P14174 1/20 0.40
KDM4E B2RXH2 4/20 0.39
HSD17B10 Q99714 3/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
MEN1 O00255 2/20 0.39
POLB P06746 2/20 0.39
MMP2 P08253 2/20 0.39
GAA P10253 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9270808 1.00 NPC1 (0.43) NPC1EIF2AK2CSNK2A2CSNK2BCSNK2A1
SCHEMBL9268022 0.78 TTR (0.51) CA1CA2KDM4ECYP3A4MAPT
SCHEMBL15764946 0.78 TTR (0.51) CA1CA2KDM4ECYP3A4MAPT
SCHEMBL23159661 0.73 ALDH1A1 (0.39) NPC1CA1NFKB1ALDH1A1SMN1; SMN2
SCHEMBL5853217 0.72 PARP1 (0.48) NPC1CA1CA2NFKB1CA4
SCHEMBL5853213 0.72 PARP1 (0.48) NPC1CA1CA2NFKB1CA4
SCHEMBL5888801 0.69 EIF2AK2 (0.46) EIF2AK2CSNK2A2CSNK2BCSNK2A1CA1
SCHEMBL5888800 0.69 EIF2AK2 (0.46) EIF2AK2CSNK2A2CSNK2BCSNK2A1CA1
SCHEMBL31501087 0.69 EIF2AK2 (0.46) EIF2AK2CSNK2A2CSNK2BCSNK2A1CA1
SCHEMBL18797918 0.69 CA1 (0.52) EIF2AK2CSNK2A2CSNK2BCSNK2A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938258-B2 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-04-10 US disclosed
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Karyopharm Therapeutics Inc. 2016-08-04 US disclosed
EP-2925750-A1 SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics, Inc. (US) 2015-10-07 EP disclosed
WO-2014085607-A1 SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2014-06-05 WO disclosed
WO-1995013266-A1 ACYLPYRROLE-ALKANOIC ACIDS AND INDOLE-2-ALKANOIC ACIDS PLUS THEIR DERIVATIVES FOR USE AS INHIBITORS OF PHOSPHOLIPASE A¿2? MERCKLE GMBH CHEM.-PHARM. FABRIK (DE) 1995-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof BCL6, MALT1, BCL3 NPC1 316/4885EIF2AK2 1105/4885CSNK2A2 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.